Table 1.
Patient and tumor characteristics.
| Characteristics | All (n = 39) | PC (n = 25) | S1 (n = 14) | |||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Median Age | 66 (33–78) | 65 (33–77) | 67 (40–73) | |||
| Age ≥65 | 22 | 56.4 | 14 | 56.0 | 8 | 57.1 |
| Age <65 | 17 | 43.6 | 11 | 44.0 | 6 | 42.9 |
| Gender | ||||||
| Male | 32 | 82.1 | 20 | 80.0 | 12 | 85.7 |
| Female | 7 | 17.9 | 5 | 20.0 | 2 | 14.3 |
| Smoking status | ||||||
| Brinkman index >1000 | 8 | 20.5 | 6 | 24.0 | 2 | 14.3 |
| Brinkman index <1000 | 31 | 79.5 | 19 | 76.0 | 12 | 85.7 |
| ECOG PS at the first administration of SCT | ||||||
| PS 0–1 | 37 | 94.9 | 24 | 96.0 | 13 | 92.9 |
| PS 2 | 2 | 5.1 | 1 | 4.0 | 1 | 7.1 |
| Primary site | ||||||
| Oral | 9 | 23.1 | 7 | 28.0 | 2 | 14.3 |
| Nasopharynx | 4 | 10.3 | 2 | 8.0 | 2 | 14.3 |
| Oropharynx | 7 | 17.9 | 3 | 12.0 | 4 | 28.6 |
| Hypopharynx | 7 | 17.9 | 5 | 20.0 | 2 | 14.3 |
| Larynx | 2 | 5.1 | 2 | 8.0 | 0 | 0.0 |
| Sinonasal tract | 7 | 17.9 | 4 | 16.0 | 3 | 21.4 |
| Others | 3 | 7.7 | 2 | 8.0 | 1 | 7.1 |
| Disease State | ||||||
| LA | 12 | 30.8 | 10 | 40.0 | 2 | 14.3 |
| DM | 11 | 28.2 | 7 | 28.0 | 4 | 28.6 |
| LA + DM | 16 | 41.0 | 8 | 32.0 | 8 | 57.1 |
| Administration line of SCT in palliative therapy | ||||||
| 2nd | 21 | 53.8 | 16 | 64.0 | 5 | 35.7 |
| 3rd | 14 | 35.9 | 8 | 32.0 | 6 | 42.9 |
| 4th | 3 | 7.7 | 1 | 4.0 | 2 | 14.3 |
| 5th | 1 | 2.6 | 0 | 0.0 | 1 | 7.1 |
| Cause of cessation of nivolumab | ||||||
| PD | 34 | 87.2 | 23 | 92.0 | 11 | 78.6 |
| AE | 4 | 10.3 | 1 | 4.0 | 3 | 21.4 |
| PD + AE | 1 | 2.6 | 1 | 4.0 | 0 | 0.0 |
ECOG PS, Eastern Cooperative Oncology Group performance status; LA, locally advanced disease; DM, distant metastasis; SCT, salvage chemotherapy; PD, progressive disease; AE, adverse event; PC, combination chemotherapy of weekly paclitaxel and cetuximab; S1, tegafur-gimestat-otastat potassium.